For people with MS who also have obesity or type 2 diabetes, GLP-1 medications may be worth discussing with a neurologist and primary care provider, though their long-term impact on MS is still unknown
Efficacy and safety of co-administered once-weekly cagrilintide 24 mg with once-weekly semaglutide 24 mg in type 2 diabetes: A multicentre, randomised, double-blind, active-controlled, phase 2 trial
Storing replacement garbage bags alongside your pens is a way of anchoring the task to something you dont need to be reminded to do
Hormone therapy is not a substitute for weight-loss medication, nutrition, or exercise
Cynthia Maxwell MD, MBA, FRCSC, DABOM (Obesity Medicine), is the Medical Content Director of First Exposure, the Vice President, Medical Affairs & System Transformation and Lead Medical Executive at Womens College Hospital and Professor, Faculty of Medicine, Department of Obstetrics and Gynaecology and Division of Maternal Fetal Medicine at the University of Toronto